Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NovoCure Limited - Ordinary Shares (NQ: NVCR )

30.80 +0.40 (+1.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Novocure
Via Business Wire
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
3 Stocks That Could Soar in a Santa Claus Rally
These stocks are primed for a holiday surge. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Where NovoCure Stands With Analysts
Via Benzinga
Why Novocure Stock Is Jumping Today
Novocure's innovative cancer therapy picked up a big win in Canada. 
Via The Motley Fool
5 Analysts Have This to Say About NovoCure
Via Benzinga
3 Top Stocks to Buy Hand Over Fist Before the End of 2022
You probably shouldn't wait for long to buy these stocks. 
Via The Motley Fool
5 Top Stocks for December
From game-changing products to indisputable growth catalysts, this list of top stocks has something for all. 
Via The Motley Fool
12 Top Stocks to Buy in December
Add this dandy dozen to your stocking this month. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
Via Benzinga
Novocure Stock: Bull vs. Bear
The company's technology has a lot of potential. But does its stock? 
Via The Motley Fool
What 4 Analyst Ratings Have To Say About NovoCure
Analysts have provided the following ratings for NovoCure (NASDAQ:NVCR) within the last quarter: 
Via Benzinga
Where NovoCure Stands With Analysts
NovoCure (NASDAQ:NVCR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
From Novocure
Via Business Wire
FedEx To Rally Over 25%? Here Are 10 Other Price Target Changes For Tuesday
Keybanc lowered Salesforce, Inc. (NYSE: CRM) price target from $210 to $200. . Keybanc analyst Michael Turits maintained an Overweight rating on the stock. Salesforce shares gained 0.5% to $154.45 in... 
Via Benzinga
3 Growth Stocks to Buy That Could Skyrocket
The future looks promising for all three of these stocks. 
Via The Motley Fool
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
Novocure (NVCR) Q3 2022 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Why Novocure Stock Is Sinking Today
An analyst's downgrade is weighing on the biotech company. 
Via The Motley Fool
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
From Novocure
Via Business Wire
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
From Novocure
Via Business Wire
Novocure Secures CE Mark for New Array
From Novocure
Via Business Wire
2 Potentially Explosive Stocks to Buy in November
Both Novocure and MercadoLibre could have good news on the way. 
Via The Motley Fool
NovoCure's Return On Capital Employed Insights
NovoCure (NASDAQ:NVCR) brought in sales totaling $131.00 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 10.7%, resulting in a loss of $26.58 million. 
Via Benzinga
3 Unstoppable Stocks That Could Double in 5 Years
The opportunities for these innovators are tremendous. 
Via The Motley Fool
NovoCure: Q3 Earnings Insights
NovoCure (NASDAQ:NVCR) reported its Q3 earnings results on Thursday, October 27, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings NovoCure beat estimated earnings... 
Via Benzinga
Novocure Reports Third Quarter 2022 Financial Results
From Novocure
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022
Upgrades 
Via Benzinga
CSX To Rally 20%? Here Are 5 Other Price Target Changes For Monday
Raymond James raised CSX Corporation (NASDAQ: CSX) price target from $31 to $33. Raymond James analyst Patrick Tyler Brown maintained the stock with an Outperform rating. CSX shares rose 1.7% to close... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.